CA3002774A1 - Programmable universal cell receptors and methods of using the same - Google Patents

Programmable universal cell receptors and methods of using the same Download PDF

Info

Publication number
CA3002774A1
CA3002774A1 CA3002774A CA3002774A CA3002774A1 CA 3002774 A1 CA3002774 A1 CA 3002774A1 CA 3002774 A CA3002774 A CA 3002774A CA 3002774 A CA3002774 A CA 3002774A CA 3002774 A1 CA3002774 A1 CA 3002774A1
Authority
CA
Canada
Prior art keywords
cell
antibody
acid sequence
catalytic
pucr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3002774A
Other languages
English (en)
French (fr)
Inventor
Gunnar Jorg Floris Kaufmann
Yanwen Fu
James T. Patterson
Yan-liang ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of CA3002774A1 publication Critical patent/CA3002774A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/15Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4274Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276Prostate specific membrane antigen [PSMA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70517CD8
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002Antibodies with enzymatic activity, e.g. abzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3002774A 2015-10-23 2016-10-24 Programmable universal cell receptors and methods of using the same Abandoned CA3002774A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562245978P 2015-10-23 2015-10-23
US62/245,978 2015-10-23
US201662382691P 2016-09-01 2016-09-01
US62/382,691 2016-09-01
PCT/US2016/058429 WO2017070654A1 (en) 2015-10-23 2016-10-24 Programmable universal cell receptors and methods of using the same

Publications (1)

Publication Number Publication Date
CA3002774A1 true CA3002774A1 (en) 2017-04-27

Family

ID=58558187

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3002774A Abandoned CA3002774A1 (en) 2015-10-23 2016-10-24 Programmable universal cell receptors and methods of using the same

Country Status (11)

Country Link
US (1) US20170112878A1 (enExample)
EP (1) EP3365016A4 (enExample)
JP (1) JP2018537076A (enExample)
KR (1) KR20180091820A (enExample)
CN (1) CN108883170A (enExample)
AU (1) AU2016341321A1 (enExample)
CA (1) CA3002774A1 (enExample)
EA (1) EA201890941A1 (enExample)
TW (1) TW201726914A (enExample)
UY (1) UY36961A (enExample)
WO (1) WO2017070654A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016341321A1 (en) * 2015-10-23 2018-06-07 Sorrento Therapeutics, Inc. Programmable universal cell receptors and methods of using the same
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2019010201A1 (en) * 2017-07-03 2019-01-10 Yale University REGULATED SMALL MOLECULE ADAPTER
KR20200076732A (ko) * 2017-11-03 2020-06-29 소렌토 쎄라퓨틱스, 인코포레이티드 Cd38-지시된 키메라 항원 수용체 작제물
WO2019173837A1 (en) * 2018-03-09 2019-09-12 Sorrento Therapeutics, Inc. Dimeric antigen receptors (dar)
AU2020369479A1 (en) * 2019-10-23 2022-05-26 University Of Florida Research Foundation, Incorporated Novel conjugation chemistry for catalytic antibody 38C2
US20230096410A1 (en) * 2020-03-06 2023-03-30 Sorrento Therapeutics, Inc. Innate Immunity Killer Cells Targeting PSMA Positive Tumor Cells
EP4225799A4 (en) * 2020-10-12 2024-11-20 Sorrento Therapeutics, Inc. CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS
EP4274852A4 (en) * 2021-01-11 2025-02-26 Eutilex Co., Ltd. BISPECIFIC EPITOP-BINDING PROTEIN WITH ANTI-4-1BB ANTIBODY AND PD-1 PROTEIN OR FRAGMENTS THEREOF AND USE THEREOF
CA3215938A1 (en) * 2021-04-23 2022-10-27 Henry Hongjun Ji Dimeric antigen receptors (dars) that bind gd2
WO2023154708A2 (en) * 2022-02-10 2023-08-17 The Scripps Research Institute Car-t therapies targeted via covalently bonded adapters

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268488B1 (en) * 1999-05-25 2001-07-31 Barbas, Iii Carlos F. Prodrug activation using catalytic antibodies
AU2004210088A1 (en) * 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring T cell response
CA2696627C (en) * 2007-08-17 2016-09-27 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
EP2483301A1 (en) * 2009-10-01 2012-08-08 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
EP2593142B8 (en) * 2010-07-12 2018-12-26 Pfizer Healthcare Ireland Multifunctional antibody conjugates
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN107188969B (zh) * 2011-04-08 2021-08-27 美国卫生和人力服务部 抗-表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途
WO2013044225A1 (en) * 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
AU2016341321A1 (en) * 2015-10-23 2018-06-07 Sorrento Therapeutics, Inc. Programmable universal cell receptors and methods of using the same

Also Published As

Publication number Publication date
WO2017070654A8 (en) 2017-06-01
EP3365016A4 (en) 2019-07-17
KR20180091820A (ko) 2018-08-16
AU2016341321A1 (en) 2018-06-07
UY36961A (es) 2017-05-31
WO2017070654A1 (en) 2017-04-27
EP3365016A1 (en) 2018-08-29
TW201726914A (zh) 2017-08-01
US20170112878A1 (en) 2017-04-27
JP2018537076A (ja) 2018-12-20
EA201890941A1 (ru) 2018-11-30
CN108883170A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
US20170112878A1 (en) Programmable universal cell receptors and method of using the same
US12466885B2 (en) Bispecific chimeric antigen receptors and encoding polynucleotides, vectors and cells thereof
US20240076352A1 (en) Chimeric Antigen Receptor
JP7490915B2 (ja) 抗メソテリンキメラ抗原受容体(car)構築物及びその使用
AU2020200751B2 (en) Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
JP2019533449A (ja) 多量体il−15に基づく分子
JP2019193652A (ja) 前立腺特異幹細胞抗原に対する抗体およびその使用
US20240352481A1 (en) Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
TW202144396A (zh) 抑制性嵌合受體架構
CA3217614A1 (en) Chimeric receptors and methods of use thereof
RU2824391C2 (ru) Иммунные клетки, экспрессирующие обратный универсальный химерный антигенный рецептор, для нацеливания на различные многочисленные антигены и способ их получения и применения для лечения рака, инфекций и аутоиммунных заболеваний
EP4159760A1 (en) Antibody specific to cd22, and use thereof
WO2025255266A1 (en) Engineered polypeptides for immune cell activation
US20150030593A1 (en) Compositions of penetration-enhanced targeting proteins and methods of use
WO2023133424A2 (en) Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides
WO2025245374A1 (en) Peptidic chimeric antigen receptor effector cell adapters and uses thereof
JP2025540340A (ja) キメラ抗原受容体
HK1222186B (en) Chimeric antigen receptor

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220426

FZDE Discontinued

Effective date: 20220426